N-[4-(thiophen-2-yl)-1,3-thiazol-2-yl]pyridin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[4-(thiophen-2-yl)-1,3-thiazol-2-yl]pyridin-2-amine
• 英文别名: pyridin-2-yl-(4-thiophen-2-yl-thiazol-2-yl)amine；Pyridin-2-yl-(4-thiophen-2-yl-thiazol-2-yl)-amine；N-pyridin-2-yl-4-thiophen-2-yl-1,3-thiazol-2-amine
• 化学式: C₁₂H₉N₃S₂
• 分子量: 259.356
• InChiKey: FHPWUMPMAJGLKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氯吡啶 、 4-噻吩-2-基-噻唑-2-胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以98%的产率得到N-[4-(thiophen-2-yl)-1,3-thiazol-2-yl]pyridin-2-amine
  参考文献：
  名称：

  2-氨基噻唑类抗结核药物的合成与评价。

  摘要：

  2-氨基噻唑系列对全球重要病原体结核分枝杆菌具有抗菌活性。我们通过设计和合成大量类似物并测试它们对结核分枝杆菌以及真核细胞的活性来探索其活性的本质。我们确定噻唑的 C-2 位可以容纳一系列亲脂性取代，而 C-4 位和噻唑核心都对变化敏感。该系列对结核分枝杆菌生长具有良好的活性，可达到亚微摩尔的最低抑制浓度。与其他细菌相比，代表性的类似物对分枝杆菌物种具有选择性，并且对复制的结核分枝杆菌具有快速杀菌作用。作用方式似乎不涉及铁螯合。我们的结论是，该系列作为新型抗结核药物具有进一步开发的潜力。

  DOI：

  10.1371/journal.pone.0155209

文献信息

• AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20150038483A1

  公开（公告）日：2015-02-05

  The present invention is related to a compound represented by formula (I) wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is —N(R 3 )—, —O—, or —S—; Y is ═C(R 4 )—, or ═N—; Z is —N(R 7 )—, —O—, or —S—; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: —(CR 2a R 2b ) n —R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物，其中R1是氢原子，取代或未取代的烷基，取代或未取代的芳香环烷基等；X是—N(R3)—，—O—或—S—；Y是═C(R4)—或═N—；Z是—N(R7)—，—O—或—S—；R2是取代或未取代的烷氧基等，或以下式表示的基团：—(CR2aR2b)n—R2c，其中R2a分别是氢原子，卤素等；R2b分别是氢原子，卤素等；附在同一碳原子上的R2a和R2b可以共同形成氧化物，取代或未取代的非芳香环烷基等；附在相邻碳原子上的两个R2a和/或附在相邻碳原子上的两个R2b可以共同形成键；R2c是取代或未取代的芳香环烷基等；n是1到3的整数；R3和R7分别是氢原子，取代或未取代的烷基等；R4和R5分别是氢原子，卤素，取代或未取代的烷基等；R6是氢原子，卤素，取代或未取代的烷基等，或其药学上可接受的盐，或包含其的药物组合物。
• Polycyclic thiazoles as potassium ion channel modulators
  申请人：Wang Xiaodong

  公开号：US20050227989A1

  公开（公告）日：2005-10-13

  The present invention provides a genus of polycyclic thiazoles that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

  本发明提供了一类多环硫唑，它们可用作钾离子通道的调节剂。本发明的调节剂可用于治疗和诊断方法。
• AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2832731A1

  公开（公告）日：2015-02-04

  The present invention is related to a compound represented by formula (I) wherein R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is -N(R3)-, -O-, or -S-; Y is =C(R4)-, or =N-; Z is -N(R7)-, -O-, or -S-; R2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: -(CR2aR2b)n-R2c, wherein R2a is each independently a hydrogen atom, halogen, or the like; R2b is each independently a hydrogen atom, halogen, or the like; R2a and R2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R2a which are attached to the adjacent carbon atoms and/or two of R2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R3 and R7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R4 and R5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物 其中 R1 是氢原子、取代或未取代的烷基、取代或未取代的芳香族羰基或类似物；X 是-N(R3)-、-O-或-S-；Y 是＝C(R4)-、或＝N-；Z 是-N(R7)-、-O-或-S-； R2 是取代或未取代的烷氧基，或类似物，或下式所代表的基团：-(CR2aR2b)n-R2c，其中 R2a 各自独立地为氢原子、卤素或类似物；R2b 各自独立地为氢原子、卤素或类似物；连接到相同碳原子上的 R2a 和 R2b 可一起形成氧代、取代或未取代的非芳香族碳环或类似物；与相邻碳原子相连的两个 R2a 和/或与相邻碳原子相连的两个 R2b 可结合在一起形成键； R2c 是取代或未取代的芳香族碳环或类似物； n 是 1 到 3 的整数； R3 和 R7 各自独立地为氢原子、取代或未取代的烷基或类似物； R4 和 R5 各自独立地为氢原子、卤素、取代或未取代的烷基或类似物； R6 是氢原子、卤素、取代或未取代的烷基或类似物、 或其药学上可接受的盐，或由其组成的药物组合物。
• US9499533B2
  申请人：——

  公开号：US9499533B2

  公开（公告）日：2016-11-22